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Low back pain as a result of degenerative disc disease imparts a large socioeconomic impact on the health care system. Traditional
concepts for treatment of lumbar disc degeneration have aimed at symptomatic relief by limiting motion in the lumbar spine, but
novel treatment strategies involving stem cells, growth factors, and gene therapy have the theoretical potential to prevent, slow, or
even reverse disc degeneration. Understanding the pathophysiological basis of disc degeneration is essential for the development
of treatment strategies that target the underlying mechanisms of disc degeneration rather than the downstream symptom of pain.
Such strategies ideally aim to induce disc regeneration or to replace the degenerated disc. However, at present, treatment options
for degenerative disc disease remain suboptimal, and development and outcomes of novel treatment options currently have to be
considered unpredictable.
1.Introduction
Low back pain (LBP) is the single most common cause
for disability in individuals aged 45 years or younger and
as a result carries tremendous weight in socioeconomic
considerations. National economic losses resulting from
LBP are estimated to exceed $100 billion per year and are
mainlyindirectduetoreducedproductivity[1].Eventhough
radiographic signs of degenerative disc disease (DDD) have
been shown in asymptomatic individuals [2] and the degree
of degeneration is by no means a marker for duration or
severity of symptoms associated to DDD, ways of limiting
disc degeneration or even inducing disc regeneration are still
desirable goals in its treatment.
Strategies for stopping or reversing disc degeneration in
the lumbar spine range from mechanical treatment options,
that rely on the traditional concept of removing the pain
generator,thedisc,andeliminatingpainbystoppingmotion,
to more recently emerging and developing treatment options
involving gene therapy, growth factors, and cell transplanta-
tions.Thetraditionalapproachofmotion-eliminatingfusion
surgery, which may be eﬀective for the treatment of pain
in some cases, may also increase the rate of degeneration at
adjacent spinal motion segments. Furthermore, this strategy
does not halt the progression of the degenerative cascade
of events that leads to pain and disability. So despite its
undeniable signiﬁcance, lumbar fusion surgery as a treat-
ment of LBP has to be regarded suboptimal, as it targets
the symptom of pain rather than its causes. The modern
molecular biology era has brought revolutionary advances in
ﬁelds such as genomics, nanotechnology, stem cell biology,
gene therapy, and tissue engineering, which together hold
tremendous therapeutic potential for clinical applications in
degenerative disorders such as DDD.
2. Pathophysiology of Disc Degeneration
2.1. Anatomy and Innervation of the Intervertebral Disc. The
intervertebral disc (IVD) is composed of the nucleus pulpo-
sus (NP) centrally, the annulus ﬁbrosus (AF) peripherally,
and the cartilaginous endplates cranially and caudally at
the junction to the vertebral bodies. Within the NP, an
abundance of proteoglycans allows for absorption of water.
This property of the NP is essential for the IVD’s handling
of axial loads. In the healthy disc, the most common type of2 Advances in Orthopedics
collagen within the NP is type II collagen. The AF surrounds
the NP and consists primarily of type I collagen.
Descriptions of the innervation of the IVD have been
published more than 20 years ago [3]. Branches of the
sinuvertebral nerve, the spinal nerves, and gray rami com-
municantes [4] are believed to be part of the neurologic
basis for discogenic back pain. An increase of nerve ﬁbers
and blood vessels in the painful disc, reaching regions of
the annulus ﬁbrosus and nucleus pulposus that are usually
aneural in the healthy disc, has been reported, and a
correlation between these ﬁndings and the expression levels
of neurotrophins has been suggested [5].
2.2. Aging and Degeneration. The process of degeneration
compares to the process of aging in many ways. However,
disc degeneration often occurs at a faster rate, making DDD
a condition often encountered in patients of working age.
Quantitative gene expression analysis in a rabbit model
suggests age to contribute uniquely to the degeneration
process when compared to an injury-induced degeneration
model [6]. With increasing age, the water content of the
IVD decreases and ﬁssures in the NP, potentially extending
into the AF, can occur, and the start of this process,
termed chondrosis intervertebralis, can mark the beginning
ofdegenerativedestructionoftheIVD,theendplates,andthe
vertebral bodies [7]. DDD is a complex degenerative process
due to age-related changes in molecular composition of the
disc. This cascade has biomechanical and often times clinical
sequelae that can result in substantial impairment in the
aﬄicted individual.
2.3. Genetic Component of Degeneration. An undeniable
genetic component to degenerative disc disease becomes
evidentwhenlookingatresultsfromtwinstudiesandstudies
involving mice with a knockout for genes suspected to play a
role in disc degeneration [8, 9]. Among the genes suggested
to be involved in DDD, are genes that code for collagens I,
IX, and XI, interleukin 1 (IL-1), aggrecan, the vitamin D
receptor, matrix metalloproteinase 3 (MMP-3), and other
proteins [10]. It is well recognized that DDD is regulated by
these andmany other genes.Interactions among those genes,
which in concert contribute substantially to DDD despite
presumably small individual contributions, as well as gene-
environment interactions, are very likely [11].
2.4. Environmental Factors. Many practitioners believe envi-
ronmental factors to be a secondary consideration to the
genetic component of DDD. Nevertheless, the inﬂuence of
environmental factors on DDD is far from negligible and
has been deﬁned in a comprehensive manner by Williams
and Sambrook in 2011 [12]. In a meta-analysis, odds ratios
for manual materials handling, frequent bending or twisting,
and whole-body vibration were calculated to be 1.51, 1.68,
and 1.39 in regard to DDD, respectively [13]. A modest
associationbetweensmoking anddiscdegenerationhasbeen
shown, suggesting possible inﬂuences of chemical exposures
[14]. Twin [15] as well as animal studies [16] have postulated
aninvolvementofnicotineindiscdegeneration,whichmight
be due to impaired blood ﬂow to the disc [17]. Furthermore,
an association of atherosclerotic lesions in the aorta and LBP,
reﬂecting a possible link between atherosclerosis and DDD,
has been reported [18].
3. ClinicalPresentation
Patientswithlumbardiscdiseaseoftenpresentwithamyriad
of symptoms including pain, radicular symptoms, and weak-
ness. LBP may be exacerbated by position and movement.
Flexion often worsens the symptoms, while extension will
relievethem.Anincreaseinpainwithextensionmayindicate
facet arthropathy.
When examining patients with presumed lumbar DDD,
it is important to exclude other potential known etiolo-
gies for their pain. Abdominal pathology including aortic
aneurysms, pancreatic disease, and renal calculi must be
excluded.Furthermore,itisimperativethatpatientsbeques-
tioned regarding other symptoms such as fevers, chills,
fatigue, and weight loss, which may be indicative of other
pathology.
4.Diagnosis
Upright plain radiographs in two planes are the initial
imaging study of choice. They aid in ruling out pathologies
such as deformity, fractures, or metastatic cancer as under-
lying causes of back pain and, often supplemented by other
imaging modalities, are evaluated for signs of degeneration.
Findings in degenerative discs include disc space narrowing,
endplate sclerosis, “vacuum” phenomenon within the disc,
and osteophytes. Flexion and extension views may be helpful
if instability is suspected.
Magnetic Resonance Imaging (MRI) is a more sensitive
imaging study for the evaluation of degenerative disc disease.
Findings on MRI scan include disc space narrowing, loss of
T2signalwithinthenucleuspulposus,endplatechanges,and
signs of internal disc derangement or tears (Figure 1). High
Intensity Zones (HIZ) have been found in close to one third
ofpatientsundergoingMRIsforlowbackpainandhavebeen
usedasamarkerforinternaldiscderangement.However,the
accuracy and reliability of these HIZs has been questioned
[19, 20].
Modic et al. were among the ﬁrst to radiologically char-
acterize vertebral endplate changes that are associated with
degenerative disc disease [21, 22]. The Modic classiﬁcation
system includes three types of changes, and grading has been
shown to be reliable and reproducible [23]. InTypeI, thereis
increased signal on the T2-weighted sequence and decreased
signal intensity on the T1 sequences indicative of marrow
edema. Type II is characterized by fatty inﬁltration of the
marrow as demonstrated by hyperintense T1 and T2 images.
Finally, Type III demonstrates hypointense signals on T1 and
T2 sequences, which corresponds to endplate sclerosis. The
Modic types are summarized by Table 1.
Pﬁrrmann et al. further examined and characterized
intervertebral disc pathology using MRI [24]. The degree
of disc degeneration were graded I through V. Grade IAdvances in Orthopedics 3
Figure 1:Discspacenarrowinganddegenerative changes attheL3-
L4 level (arrow) on sagittal T2-weighted MRI.
Table 1: Modic changes as illustrated by Jones et al. [23].
Type T1 MRI signal intensity T2 MRI signal intensity
I hypointense hyperintense
II hyperintense iso- or hyperintense
III hypointense hypointense
Table 2: Pﬁrrmann grades as illustrated by Pﬁrrmann et al. [24].
Grade Structure
Distinction
(nucleus
and
annulus)
T2 MRI signal
intensity
Disc
space
height
I white,
homogenous clear
isointense to
cerebrospinal
ﬂuid
(hyperintense)
normal
II inhomogeneous,
with banding clear
isointense to
cerebrospinal
ﬂuid
(hyperintense)
normal
III gray,
inhomogeneous unclear intermediate
normal
to
decreased
IV gray to black,
inhomogenous
no
distinction
intermediate to
hypointense
normal
to
decreased
V black,
inhomogenous
no
distinction hypointense collapsed
discs are white, and homogenous on T2 sequences. Grade II
discs are white, but somewhat inhomogenous with banding.
Grade III discs are grey with unclear distinction between the
nucleus and annulus. Grade IV discs are inhomogenous and
dark without distinction between the nucleus and annulus.
Finally, Grade V discs demonstrate a collapsed disc space.
The Pﬁrrmann grading system is depicted by Table 2.
While plain radiographs and MRI provide information
regarding the health of the intervertebral segment, they do
not provide any information regarding the segments impact
on clinical symptoms. The use of discography has attempted
to identify speciﬁc degenerated discs as pain generators [25].
Provocative discography involves the injection of contrast
dye into the nucleus. Computed tomography is used to
evaluate for extravasation of dye indicating annular tears.
The patient’s symptoms and intradiscal pressure during
the injection are also recorded. If the pain on injection is
similar to their back pain, then the discogram is considered
concordant. Also, if pain is produced at low pressures, it is
felt that there is symptomatic annular disruption or internal
derangement. However, if the pain is diﬀerent or produced
at high pressures of injection, the test is often considered
discordant. Still, low-pressure discography has been found
to have false positive rates of up to 25% in asymptomatic
individuals and may accelerate disc degeneration [26, 27].
5.TreatmentStrategiesforLumbar
Degenerative DiscDisease
5.1. Mechanical Concepts of Lumbar Disc Regeneration.
Spinal fusion surgery is a recognized treatment option of
LBP but its eﬃcacy and success remain controversial. It
c a nb ea c h i e v e db yav a r i e t yo fa p p r o a c h e sa n dt e c h n i q u e s ,
including posterolateral fusion, anterior lumbar interbody
fusion, and posterior lumbar interbody fusion. Minimally
invasiveapproachestothelumbarspineforinterbodyfusion,
such as lateral lumbar interbody fusion, have been gaining
popularity within the last 5 years [28].
While fusion procedures oﬀer a way of eliminating
motion between spinal segments, and thus alleviate disco-
genic pain associated to degenerative changes, they address
only a symptom and not the cause of DDD. Furthermore,
there are signiﬁcant concerns regarding alterations in adja-
cent segment motion, which may lead to the introduction
of adjacent segment degeneration [29–31]. As a result,
motion preserving procedures have been introduced to assist
in preventing adjacent segment changes. Disc arthroplasty
has the purported advantage of removing the degenerated
intervertebral disc and replacing it with a prosthesis that
will allow motion between the segments. Clinical trials have
shown equivalent results compared with circumferential
fusion for the treatment of discogenic pain [32]. In a
two-year follow-up study, total disc replacement patients
compared favorably to an arthrodesis control group in terms
of pain relief and recovery, but a potential early time point
patient bias in favor of the arthroplasty group necessitates
a longer followup and concern was expressed in regard
to long-term polyethylene wear in total disc replacements
with a polyethylene component [33]. Furthermore, the
purportedadvantagesofpreventingadjacentsegmentdisease
are unclear and require additional long-term results [34].
Another potential motion-preserving surgery involves
posterior dynamic stabilization. These systems involve place-
ment of pedicle screws across a motion segment connected
by a ﬂexible graft. These devices are designed to restrict
motion across the interspace to limit discogenic pain [35].
Early followup of this technique has demonstrated some4 Advances in Orthopedics
promising result in the treatment of discogenic back pain
with regard to improved VAS and ODI scores [36, 37].
However, longer-term studies have demonstrated adjacent
segment disease in 29–47% of patients [38–40].
5.2. Cell-Based Therapies and Growth Factors in Lumbar Disc
Degeneration. While there are a variety of invasive, surgical
options for the treatment of lumbar degenerative disc dis-
ease, recent emphasis has been directed at the reversal of disc
degeneration or the replacement of the aﬀected disc. Various
therapies have been investigated including biologic growth
factors, stem cells, and gene transplant. While these novel
therapeutic modalities have shown some early promising
results with regards to reversal of the degenerative cascade,
their clinical eﬀects and long-term results are uncertain
[41]. It is also unclear, whether diﬀerentiation of stem cells
into mature tissues may cause them to express immuno-
genic markers, which ultimately may result in stem cell
rejections.
In 2002, Bone Morphogenetic Protein (BMP) was ap-
proved as a bone graft substitute for anterior lumbar
interbodyfusion(ALIF),butinadditiontoitsosteoinductive
properties, BMP also demonstrated some potential for the
treatment of disc disease [42]. Current human and animal
studies have shown upregulation of BMP-2 and -7 in aging
discs. This upregulation has been found to have an antiapop-
totic eﬀecton the cells of the nucleus pulposus [43]. Also, the
introduction of BMP-2 into intervertebral discs has resulted
in increased extracellular matrix production [44]. However,
the direct introduction of BMP into the intervertebral disc
may lead to potential undesired osteogenic eﬀects. In recent
years, concerns about the safety of BMP-2 have arisen
following reports of adverse reactions attributable to its use
in ALIF and its oﬀ-label use in other spinal fusions [45–47].
In2008,theFDApublishedapublichealthnotiﬁcationabout
potentially life-threatening complications associated with
use of BMP in cervical spine fusion [48]. To date, the safety
of recombinant BMP-2 as a bone graft substitute remains
controversial. Recent studies have shown the potential for
the drug simvastatin to induce chondrogenesis and the
production of Type II collagen and aggrecan through BMP-
mediated pathways [49].
Transplantation of stem cells has emerged as another
promising treatment strategy for DDD [40, 50–52]. Recent
animal studies have shown increased extracellular matrix
when autologous disc-derived chondrocytes were intro-
duced into a canine disc degeneration model. Furthermore,
recent human trial involving the introduction of autologous
chondrocytes into postdiscectomy patients has resulted in
decreased pain at 2 years compared with controls. Also, there
wasincreaseddischydrationatthetreatedlevelsandadjacent
levels as evidenced by MRI evaluation [53].
Analternativetechniquetochrondrocytetransplantation
has been the use of adipocyte progenitor cells. The advantage
to this technique is the relative abundance of adipose-
derived stem cell when compared to chondrocytic stem
cells. In a rat degenerative disc disease model, transplanted
adipose-derived stem cells resulted in increased extracellular
matrix production, minimally decreased disc height, and
improved discal hydration when compared to controls
[54].
Finally, another promising type of stem cells for future
investigation are bone-marrow-derived stem cells. In vitro
studies have demonstrated that these cells have similar
chondrogenic capacity when compared to nucleu-pulposus-
derived cells [55]. However, in vivo studies are needed to
conﬁrm their potential eﬃcacy, and any strategy involving
the introduction of new cells into the human intervertebral
disc to induce regeneration would have to account for the
increased demand of nutritional supply by the increasing
numberofcellsortheincreasedactivityofpreviouslypresent
cells [56].
5.3. Gene Therapy in Lumbar Disc Degeneration. Trans-
duction of genes that have the potential to interfere with
disc degeneration or even induce disc regeneration is a
concept recently applied to DDD by researchers. This
strategy requires identiﬁcation of relevant genes that play
a role in the disc degeneration cascade, as well as ways
of delivering those potentially therapeutic genes into disc
cells. This can be obtained by so-called gene vector systems,
which include a variety of viral and, more recently, nonviral
vectors [57]. Safety issues are imminent to the use of vectors,
and absence of adverse eﬀects is imperative to any vector
system.
Early studies used viral vectors to deliver marker genes
into discs in vitro and in vivo [51, 58]. The ﬁrst gene
with potentially beneﬁcial eﬀects on disc degeneration to be
experimentally delivered to the IVD in an animal model was
TGF-β1[ 59]. A similar approach of initial transduction of a
marker gene was taken by Moon et al. to deliver genes into
human IVD cells [60].
Additionally, other growth factors [61], inhibitors of
metalloproteinases [62], and also a transcription factor,
Sox-9 [63], have received consideration as possible targets
for gene therapy for DDD. Following identiﬁcation of
ADAMTS5 as a contributor to cartilage degradation in a
mouse model [64], ADAMTS5 small interference RNA was
successfully used in a rabbit model to suppress degradation
of NP tissue [65]. A similar approach was used to target
caspase 3, a main executor of apoptosis, in a rabbit model
[66]. Future in vivo studies linking theoretical beneﬁts of
any of these gene therapy approaches to situations possibly
encountered in clinical practice are desirable [67]a n d
comprise the long-term perspective of applying gene therapy
as a strategy to treat the underlying mechanism of disc
degeneration.
5.4. Summary. Degenerative lumbar disc disease and result-
ing low back pain impart a large socioeconomic impact on
the health care system. Disc degeneration is a multifactorial
occurrence with a strong genetic component. Age and
environmentalfactorscontributetothedegenerativeprocess.
While current strategies aim to remove the pain generator
through surgery, future, emerging modalities aim to reverse
the degenerative cascade through the use of biologics andAdvances in Orthopedics 5
gene modiﬁcation. Advances in ﬁelds such as genomics,
nanotechnology, stem cell biology, gene therapy, and tis-
sue engineering have tremendous therapeutic potential for
clinical applications in degenerative disorders such as DDD,
but novel treatment strategies for lumbar disc degeneration
require further evaluation in preclinical and clinical trials.
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